Why the study?
Does dosing doxorubicin and etoposide based on adjusted body surface area provide comparable pharmacokinetics to nonobese patients in a morbidly obese pediatric patient?
Does dosing doxorubicin and etoposide based on adjusted body surface area provide comparable pharmacokinetics to nonobese patients in a morbidly obese pediatric patient?
Dosing doxorubicin and etoposide based on adjusted body surface area in a morbidly obese pediatric patient resulted in comparable pharmacokinetics to nonobese patients and a complete clinical response without specific toxicity.
May support adjusted BSA dosing in morbidly obese pediatric patients; hypothesis-generating and requires prospective validation.
This case report presents the pharmacokinetics of doxorubicin and etoposide in a 14-year-old morbidly obese (body mass index: 46.3 kg/m2) male patient with Hodgkin disease. Dosing based on an adjusted body surface area resulted in a dose reduction by approximately 25% as compared to dosing based on actual body surface area. Plasma clearance of doxorubicin as well as plasma clearance and elimination rate of etoposide for this patient was comparable to pharmacokinetic data from nonobese pediatric patients. The therapy was well tolerated without any specific toxicity and a complete response was obtained after 2 scheduled courses, with the patient in complete remission 25 months after end of treatment.
No takes yet. Share an insight, caveat, or question.
Ritzmo et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: